A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)

* Chronic HCV infection prior to study enrollment. * Screening laboratory result indicating HCV genotype 1-infection. * Subject has plasma HCV RNA level greater than 10,000 IU/mL at Screening. * Per local standard, subject is considered to be non-cirrhotic or to have compensated cirrhosis.

* History of severe, life-threatening or other significant sensitivity to any drug. * Positive test result for Hepatitis B surface antigen (HBsAg) or anti-Human Immunodeficiency Virus antibody (HIV Ab). * Prior therapy for the treatment of HCV. * Any current or past clinical evidence of Child Pugh B or C classification of clinical history of liver decompensation including ascites (noted on physical exam), variceal bleeding or hepatic encephalopathy. * Any cause of liver disease other than chronic HCV infection.